Victory Capital Management Inc. trimmed its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 19.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,662,668 shares of the company's stock after selling 405,240 shares during the period. Victory Capital Management Inc. owned 3.37% of Prestige Consumer Healthcare worth $129,838,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently added to or reduced their stakes in PBH. Kestra Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at approximately $27,000. Huntington National Bank grew its holdings in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after buying an additional 181 shares during the last quarter. International Assets Investment Management LLC grew its holdings in Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock valued at $83,000 after buying an additional 1,138 shares during the last quarter. Covestor Ltd increased its position in Prestige Consumer Healthcare by 95.6% during the third quarter. Covestor Ltd now owns 1,338 shares of the company's stock worth $96,000 after buying an additional 654 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after acquiring an additional 220 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts recently commented on the company. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Friday, January 24th. Oppenheimer lifted their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, DA Davidson increased their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $92.60.
View Our Latest Stock Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Trading Up 2.3 %
Prestige Consumer Healthcare stock traded up $2.01 during trading on Friday, reaching $89.10. The company had a trading volume of 604,737 shares, compared to its average volume of 328,521. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $89.65. The stock's 50 day moving average price is $80.80 and its two-hundred day moving average price is $77.83.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
Prestige Consumer Healthcare Profile
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
